No Racial Differences Found in Access to Biologics: A Population-Based Study of Psoriasis Patients in the United States.

Background: Conflicting evidence exists regarding the role of race in access to biologics for patients with psoriasis.

Objective: To compare biologic use among adult and pediatric United States psoriasis patients of different racial backgrounds.

Methods: Population-based study of US psoriasis patients using the 2003 to 2018 Medical Expenditure Panel Survey (MEPS).

Management of Psoriasis With Topicals: Applying the 2020 AAD-NPF Guidelines of Care to Clinical Practice.

Topical medications have high utility in the treatment of psoriasis because of their localized effect and ability to be used as both monotherapy and adjunctive therapy. The American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) published guidelines in 2020 regarding the management of psoriasis with topical therapies. These guidelines are a framework that assist clinicians treating psoriasis patients with topical agents including steroids, calcineurin inhibitors (CNIs), vitamin D analogues, retinoids (tazarotene), emollients, keratolytics (salicylic acid), anthracenes (anthralin), and keratoplastics (coal tar).

Comparison of Guidelines for the Use of Interleukin-17 Inhibitors for Psoriasis in the United States, Britain, and Europe: A Critical Appraisal and Comprehensive Review.

Background: Interleukin (IL)-17 inhibitors are a newer class of biologic used to treat patients with moderate-to-severe plaque psoriasis and psoriatic arthritis.

Objective: We compared evidence-based clinical practice guidelines (CPGs) from leading dermatological organizations for the use of IL-17 inhibitors in psoriasis.

Methods: Guidelines from the Joint American Academy of Dermatology-National Psoriasis Foundation (AAD-NFP) Guidelines, British Association of Dermatologists guidelines (BAD), and European S3 group (ES3) were all reviewed and compared.

Translating the 2019 AAD-NPF Guidelines of Care for Psoriasis With Attention to Comorbidities.

In April 2019, the American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) released a set of guidelines regarding the management of psoriasis with a focus on its extracutaneous manifestations-comorbidities, mental health, psychosocial wellness, and quality of life (QOL). These guidelines provide the most up-to-date evidence on the screening and treatment recommendations for these disease comorbidities. The purpose of this review is to present the recommendations in a form that can be easily applied in clinical practice.

Differences in health care resource utilization and costs for keratinocyte carcinoma among racioethnic groups: A population-based study.

Background: As the United States becomes more diverse, determining differences in health care utilization and costs in the management of skin cancers is fundamental to decision-making in health care resource allocation and improving care for underserved populations.

Objective: To compare health care use and costs among non-Hispanic White, Hispanic White, and non-Hispanic Black patients with keratinocyte carcinoma.

Methods: A nationwide cross-sectional study was performed using Medical Expenditure Panel Survey data from 1996 to 2015.

Comparison of guidelines for the use of Ustekinumab for psoriasis in the United States, Europe, and the United Kingdom: A critical appraisal and comprehensive review.

The aim of this review is to compare and contrast evidence-based clinical practice guidelines from global dermatological organizations for the use of ustekinumab in psoriasis. Clinical practice guidelines from the American Academy of Dermatology, National Psoriasis Foundation, British Association of Dermatologists, and European S3 were reviewed and compared. Practice guidelines from the three dermatological organizations are similar with regards to treatment dosage and initiation but differ in their recommendations for baseline screening and interval laboratory monitoring, treatment in patients undergoing surgery or receiving live vaccines, and treatment contraindications.

Translating the 2020 AAD-NPF Guidelines of Care for the Management of Psoriasis With Systemic Nonbiologics to Clinical Practice.

In 2020, the American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) released a set of guidelines for the management of psoriasis in adults with systemic nonbiologic therapies, including acitretin, apremilast, cyclosporine, fumaric acid esters, methotrexate, and tofacitinib. This review addresses dosing, efficacy, toxicity, drug-related interactions, and contraindications alongside evidence-based treatment recommendations for each systemic therapy. Important considerations for treatment such as drug selection, initiation of therapy, drug monitoring, and patient management also are discussed.

Differences in Depression and Distress Between Acne Patients on Isotretinoin vs Oral Antibiotics.

Background: Little is known regarding differential effects of systemic anti-acne treatments on mental health.

Objective: To determine whether differences exist in mental health outcomes between acne patients treated with isotretinoin versus oral antibiotics (doxycycline, minocycline, or tetracycline).

Methods: Population study utilizing the 2004-2017 Medical Expenditure Panel Survey.

Who sees you matters: a population study examining topical corticosteroid prescribing patterns between primary care providers and dermatologists for atopic dermatitis.

Background: Many patients with atopic dermatitis seek care from both primary care physicians and dermatologists. However, little is known regarding topical corticosteroid prescribing patterns among these specialties.

Objective: We sought to determine if differences exist in topical corticosteroid prescribing patterns among dermatologists, family medicine physicians, and internal medicine physicians.

Topical Agents Currently in Phase II or Phase III Trials for Atopic Dermatitis.

Mild to moderate atopic dermatitis (AD) occurs frequently in children and adults and is usually managed through the use of pharmacologic treatments, such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs), and good skin care practices. As chronic TCS or TCI can lead to the development of adverse effects, there is a need for safe, alternative treatments for patients with resistant AD. A systemic literature review was performed to examine the safety and efficacy of topical agents currently in phase II and phase III clinical trials for AD.

Translating the 2019 AAD-NPF Guidelines of Care for the Management of Psoriasis With Phototherapy.

In July 2019, the American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) released an updated set of guidelines regarding the use of phototherapy to manage adult patients with psoriasis. Treatment with light of various wavelengths is reviewed, with a focus on modalities utilizing UV light. These guidelines provide the most up-to-date evidence regarding dosing, indications, contraindications, and adverse effects of phototherapy alone and in combination with other treatments for psoriasis.

Language proficiency and biologics access: a population study of psoriasis patients in the United States.

Background: Language proficiency plays an important role in healthcare choices and access. Differences in access to biologic medications exist, but it is unknown how much English proficiency influences access in US psoriasis patients.

Objective: To compare biologic medication use for psoriasis patients with differing English proficiency levels.

Clinical management of psoriasis patients during the COVID-19 pandemic.

Psoriasis is a systemic immune-mediated inflammatory disease that requires consistent treatment and follow-up. Given that COVID-19 will persist in the coming years, dermatologists need to adjust their practices accordingly to care for their patients, particularly psoriasis patients managed with systemic therapies. We provide guidelines for optimizing care for psoriasis patients, including considerations for medication management, lifestyle adjustments, and utilization of telemedicine.